Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3 USD | +1.69% | -1.95% | -27.05% |
06-05 | Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target | MT |
05-08 | Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.05% | 89.01M | |
+18.79% | 125B | |
+13.74% | 108B | |
-7.63% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-14.18% | 16.37B | |
+1.57% | 13.58B | |
+27.50% | 11.66B |
- Stock Market
- Equities
- RLMD Stock
- News Relmada Therapeutics, Inc.
- Sector Update: Health Care